R. Haïat and G. Leroy, Troubles du rythme: les enseignements des grands essais cliniques, 2004.

J. Heeringa, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, European Heart Journal, vol.27, issue.8, pp.949-953, 2006.
DOI : 10.1093/eurheartj/ehi825

A. Charlemagne, Epidemiology of atrial fibrillation in France: Extrapolation of international epidemiological data to France and analysis of French hospitalization data, Archives of Cardiovascular Diseases, vol.104, issue.2
DOI : 10.1016/j.acvd.2010.11.012

J. W. Magnani, Atrial Fibrillation: Current Knowledge and Future Directions in Epidemiology and Genomics, Circulation, vol.124, issue.18, pp.1982-1993, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.039677

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial Fibrillation: A Major Contributor to Stroke in the Elderly, Archives of Internal Medicine, vol.147, issue.9, pp.1561-1564, 1987.
DOI : 10.1001/archinte.1987.00370090041008

V. Fuster, 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.57, issue.11, pp.101-198, 2006.
DOI : 10.1016/j.jacc.2010.09.013

P. A. Wolf, T. R. Dawber, H. E. Thomas, &. Jr, and W. B. Kannel, Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study, Neurology, vol.77, issue.16, pp.973-977, 1978.
DOI : 10.1212/01.wnl.0000407150.80523.a4

P. A. Wolf, L. J. Kerzner, A. V. Hiltbrunner, and W. Kannel, Stroke Resulting from Nonvalvular Atrial Fibrillation, Journal of the American Geriatrics Society, vol.8, issue.7, pp.751-757, 1984.
DOI : 10.1111/j.1532-5415.1984.tb04175.x

J. L. Halperin and R. G. Hart, Atrial fibrillation and stroke: new ideas, persisting dilemmas, Stroke, vol.19, issue.8, pp.937-941, 1988.
DOI : 10.1161/01.STR.19.8.937

E. Heart and R. Association, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur. Heart J, vol.31, pp.2369-2429, 2010.

A. J. Camm, 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.2719-2747, 2012.
DOI : 10.1016/j.rec.2012.11.003

B. F. Gage, Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin, Circulation, vol.110, issue.16, pp.2287-2292, 2004.
DOI : 10.1161/01.CIR.0000145172.55640.93

G. Y. Lip, The role of aspirin for stroke prevention in atrial fibrillation, Nature Reviews Cardiology, vol.27, issue.10, pp.602-606, 2011.
DOI : 10.1038/nrcardio.2011.112

I. M. Ogilvie, S. A. Welner, W. Cowell, and G. Y. Lip, Ischaemic stroke and bleeding rates in ???real-world??? atrial fibrillation patients, Thrombosis and Haemostasis, vol.106, issue.1, pp.34-44, 2011.
DOI : 10.1160/TH10-10-0674

J. B. Olesen, Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ???real world??? nationwide cohort study, Thrombosis and Haemostasis, vol.106, issue.4, pp.739-749, 2011.
DOI : 10.1160/TH11-05-0364

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-867, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

A. M. Holbrook, Systematic Overview of Warfarin and Its Drug and Food Interactions, Archives of Internal Medicine, vol.165, issue.10, pp.1095-1106, 2005.
DOI : 10.1001/archinte.165.10.1095

Z. J. Eapen, Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation, Journal of Cardiac Failure, vol.20, issue.1, pp.23-30, 2014.
DOI : 10.1016/j.cardfail.2013.11.006

S. Chen, One-Year Adherence to Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Long-term Risk of Recurrent Events, Journal of Managed Care Pharmacy, vol.19, issue.4
DOI : 10.18553/jmcp.2013.19.4.291

D. Suh, J. C. Choi, J. Schein, S. Kim, and W. W. Nelson, Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients, Current Medical Research and Opinion, vol.29, issue.7
DOI : 10.1185/03007995.2013.795142

S. D. Fihn, The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics

A. L. Gulløv, B. G. Koefoed, and P. Petersen, Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation, Archives of Internal Medicine, vol.159, issue.12, pp.1322-1328, 1999.
DOI : 10.1001/archinte.159.12.1322

F. D. Mann, M. Hurn, and T. B. Magath, Observations on the Conversion of Prothrombin to Thrombin, Experimental Biology and Medicine, vol.66, issue.1, pp.33-35, 1947.
DOI : 10.3181/00379727-66-15973

O. D. Ratnoff, AN ACCELERATING PROPERTY OF PLASMA FOR THE COAGULATION OF FIBRINOGEN BY THROMBIN 12, Journal of Clinical Investigation, vol.33, issue.8, pp.1175-1182, 1954.
DOI : 10.1172/JCI102990

O. 'brien, P. J. Mureebe, and L. , Direct thrombin inhibitors, J. Cardiovasc. Pharmacol. Ther, vol.17, pp.5-11, 2012.

S. J. Connolly, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12
DOI : 10.1056/NEJMoa0905561

M. R. Patel, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11
DOI : 10.1056/NEJMoa1107039

J. Van-ryn, The Discovery of Dabigatran Etexilate, Frontiers in Pharmacology, vol.4, p.12, 2013.
DOI : 10.3389/fphar.2013.00012

M. D. Ezekowitz, Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study), The American Journal of Cardiology, vol.100, issue.9
DOI : 10.1016/j.amjcard.2007.06.034

J. W. Eikelboom, Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial", Circulation, vol.125, issue.3, pp.2363-2372, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.061721

K. Uchino and A. Hernandez, Dabigatran Association With Higher Risk of Acute Coronary Events, Archives of Internal Medicine, vol.172, issue.5, pp.397-402, 2012.
DOI : 10.1001/archinternmed.2011.1666

R. Artang, E. Rome, J. D. Nielsen, and H. J. Vidaillet, Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors, The American Journal of Cardiology, vol.112, issue.12, pp.1973-1979, 2013.
DOI : 10.1016/j.amjcard.2013.08.027

S. Schulman, Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism, New England Journal of Medicine, vol.368, issue.8, pp.709-718, 2013.
DOI : 10.1056/NEJMoa1113697

URL : https://hal.archives-ouvertes.fr/hal-00935796

B. I. Eriksson, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, vol.370, issue.9591, pp.949-956, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

B. I. Eriksson, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-2185, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

S. Schulman, Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-2352, 2009.
DOI : 10.1056/NEJMoa0906598

URL : https://hal.archives-ouvertes.fr/ujm-00439704

D. Center, . Evaluation, and . Research, Drug Safety and Availability -FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran), 2013.

F. Mini, Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate), 2013.

. Auspar, Dabigatran etexilate mesilate, 2011.

Y. Huang, J. Moon, and J. B. Segal, A Comparison of Active Adverse Event Surveillance Systems Worldwide, Drug Safety, vol.22, issue.Suppl 1, pp.581-596, 2014.
DOI : 10.1007/s40264-014-0194-3

J. Hippisley-cox, C. Coupland, and R. Logan, Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis, BMJ, vol.331, issue.7528, pp.1310-1316, 2005.
DOI : 10.1136/bmj.331.7528.1310

A. Wahab, I. Pratt, N. L. Kalisch, L. M. Roughead, and E. E. , Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia, Drug Safety, vol.62, issue.1, pp.53-64, 2014.
DOI : 10.1007/s40264-013-0124-9

L. Mellemkjaer, Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark, British Journal of Clinical Pharmacology, vol.10, issue.2, pp.173-181, 2002.
DOI : 10.1046/j.0306-5251.2001.01220.x

P. Latry, M. Molimard, B. Bégaud, and K. Martin-latry, How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database, European Journal of Clinical Pharmacology, vol.19, issue.3, pp.743-748, 2010.
DOI : 10.1007/s00228-010-0819-0

URL : https://hal.archives-ouvertes.fr/hal-00589490

N. Mantel, Synthetic Retrospective Studies and Related Topics, Biometrics, vol.29, issue.3, p.479, 1973.
DOI : 10.2307/2529171

F. D. Liddell, J. C. Mcdonald, D. C. Thomas, and S. Cunliffe, Methods of Cohort Analysis: Appraisal by Application to Asbestos Mining, Journal of the Royal Statistical Society. Series A (General), vol.140, issue.4, p.469, 1977.
DOI : 10.2307/2345280

M. Wang, Y. Y. Shugart, S. R. Cole, and E. A. Platz, A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.3
DOI : 10.1158/1055-9965.EPI-08-0839

R. Pisters, A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, Chest, vol.138, issue.5, pp.1093-1100, 2010.
DOI : 10.1378/chest.10-0134

J. P. Piccini, Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke, European Heart Journal, vol.35, issue.4, pp.250-256, 2014.
DOI : 10.1093/eurheartj/eht483

D. D. Mcmanus, Atrial Fibrillation and Outcomes in Heart Failure With Preserved Versus Reduced Left Ventricular Ejection Fraction, Journal of the American Heart Association, vol.2, issue.1, p.5694, 2013.
DOI : 10.1161/JAHA.112.005694

Y. Miyasaka, Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades, European Heart Journal, vol.27, issue.8, pp.936-941, 2006.
DOI : 10.1093/eurheartj/ehi694

W. Saliba and G. Rennert, CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation, The American Journal of Medicine, vol.127, issue.1, pp.45-52, 2014.
DOI : 10.1016/j.amjmed.2013.10.004

V. Tagalakis, Men had a Higher Risk of Recurrent Venous Thromboembolism than Women: A Large Population Study, Gender Medicine, vol.9, issue.1, pp.33-43, 2012.
DOI : 10.1016/j.genm.2011.12.002

P. Klement, The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model, Journal of Thrombosis and Haemostasis, vol.94, issue.Suppl. 3, pp.587-594, 2003.
DOI : 10.1046/j.1538-7836.2003.00060.x

T. Furugohri, N. Sugiyama, Y. Morishima, and T. Shibano, Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system, Thrombosis and Haemostasis, vol.106, issue.6
DOI : 10.1160/TH11-06-0382

C. Christersson, J. Oldgren, L. Wallentin, and A. Siegbahn, Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction, Journal of Internal Medicine, vol.370, issue.Suppl 1, pp.215-223, 2011.
DOI : 10.1111/j.1365-2796.2011.02354.x

B. Dale, Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?, Journal of Thrombosis and Thrombolysis, vol.142, issue.5, pp.295-301, 2013.
DOI : 10.1007/s11239-012-0857-9

E. Tremblay, Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments. 56 (Institut national d'excellence en santé et en services sociaux, 2013.

R. Sørensen, Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, BMJ Open, vol.3, 2013.

D. J. Graham, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation

K. Martin-latry and B. Bégaud, Pharmacoepidemiological research using French reimbursement databases: yes we can!, Pharmacoepidemiology and Drug Safety, vol.60, issue.Suppl 6, pp.256-265, 2010.
DOI : 10.1002/pds.1912

P. M. Coloma, Electronic healthcare databases for active drug safety surveillance: is there enough leverage?, Pharmacoepidemiology and Drug Safety, vol.356, issue.17, pp.611-621, 2012.
DOI : 10.1002/pds.3197

P. M. Coloma, Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project, Pharmacoepidemiology and Drug Safety, vol.3, issue.12, pp.1-11, 2011.
DOI : 10.1002/pds.2053

E. M. Rodriguez, J. A. Staffa, and D. J. Graham, The role of databases in drug postmarketing surveillance, Pharmacoepidemiology and Drug Safety, vol.9, issue.5, pp.407-410, 2001.
DOI : 10.1002/pds.615

G. Trifirò, Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?, Pharmacoepidemiology and Drug Safety, vol.15, issue.12, pp.1176-1184, 2009.
DOI : 10.1002/pds.1836

K. Thorne, Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice, Internal Medicine Journal, vol.38, issue.3, pp.261-265, 2014.
DOI : 10.1111/imj.12370

M. Pirmohamed, A. M. Breckenridge, N. R. Kitteringham, and B. K. Park, Fortnightly review: Adverse drug reactions, BMJ, vol.316, issue.7140, pp.1295-1298, 1998.
DOI : 10.1136/bmj.316.7140.1295

URL : http://www.bmj.com/cgi/content/short/316/7140/1295

K. Fattinger, Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine, British Journal of Clinical Pharmacology, vol.54, issue.2, pp.158-167, 2000.
DOI : 10.1046/j.1365-2125.1996.04376.x

P. Pouyanne, F. Haramburu, J. L. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

S. Thiesen, Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children ??? a prospective observational cohort study of 6,601 admissions, BMC Medicine, vol.7, issue.1
DOI : 10.1371/journal.pone.0046022

A. L. Phillips, Hospital admissions caused by adverse drug events: an Australian prospective study, Australian Health Review, vol.38, issue.1, pp.51-57, 2014.
DOI : 10.1071/AH12027

L. Ibáñez, J. R. Laporte, and X. Carné, Adverse Drug Reactions Leading to Hospital Admission, Drug Safety, vol.6, issue.6, pp.450-459, 1991.
DOI : 10.2165/00002018-199106060-00005

F. Salvi, Adverse Drug Events as a Cause of Hospitalization in Older Adults, Drug Safety, vol.15, issue.12
DOI : 10.1007/BF03319101